New inhaled treatment for respiratory viruses in adults and the elderly
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV
This study is testing a new inhaled treatment called MM004 that aims to help older adults and those with weakened immune systems fight off respiratory viruses like RSV and MPV, by delivering medicine directly to the lungs where it's needed most.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project ID | NIH-10810719 on NIH RePORTER |
What this research studies
This research focuses on developing a bispecific inhaled immunotherapy called MM004 to treat respiratory syncytial virus (RSV) and metapneumovirus (MPV), which are significant causes of respiratory illness in older adults and immunocompromised individuals. The approach involves creating a topical monoclonal antibody that targets these viruses directly in the airways, potentially providing a more effective treatment option than current therapies. By utilizing a unique 'muco-trapping' mechanism, the treatment aims to enhance the delivery of the antiviral directly where it is needed most. Patients participating in this research may receive this innovative therapy as part of the clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults and immunocompromised individuals who are at high risk for severe respiratory illness caused by RSV and MPV.
Not a fit: Patients who are not at risk for RSV or MPV infections, such as healthy young adults, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for RSV and MPV, significantly reducing morbidity and mortality in affected patients.
How similar studies have performed: While there are currently no effective treatments for MPV, the approach of using bispecific monoclonal antibodies for respiratory viruses is novel and has not been extensively tested in this context.
Where this research is happening
Morrisville, UNITED STATES
- Mucommune, LLC — Morrisville, United States (Active)
Researchers
- Principal investigator: Cone, Richard — Mucommune, LLC
- Study coordinator: Cone, Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.